ArticleBMC cancer2026
FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe LEAP-002 study showed that pembrolizumab plus lenvatinib did not provide statistically significant prognostic improvement over lenvatinib monotherapy in advanced hepatocellular carcinoma (HCC). This study investigated the potential protective role of high fibroblast growth factor receptor 4 (FGFR4) expression, a therapeutic target of lenvatinib, in immunotherapy for HCC.
methodsThe Kaplan Meier plotter database was used to assess the impact of FGFR4 expression on immunotherapy outcomes; the TCGA-LIHC dataset was analyzed for correlations between FGFR4 expression, immune checkpoint gene profiles, and immune cell infiltration; and single-cell RNA sequencing (scRNA-seq) data from GSE149614 were used to examine interactions between high- and low-FGFR4 cancer cell subpopulations and immune cells. Validation was performed in tumor specimens from HCC patients treated with lenvatinib in combination with PD-1 inhibitors.
resultsHigh FGFR4 expression predicted favorable immunotherapy outcomes and correlated with immune checkpoint genes such as PCDH1 and CD274, along with reduced M2 macrophage infiltration in TCGA-LIHC. scRNA-seq analysis showed FGFR4 enrichment in cancer cells, with high-FGFR4 cancer cells displaying a unique CXCL1-CXCR2 signaling axis with macrophages. High FGFR4 expression activated the MAPK pathway and increased JUN(+) transcriptional activity, showing a significant positive correlation with CXCL1 levels. In HCC patients treated with lenvatinib plus PD-1 inhibitors, high FGFR4 expression was linked to enhanced M1 macrophage polarization and elevated PD-L1 expression, whereas low FGFR4 expression correlated with better clinical outcomes.
conclusionFGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.